

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 698 333 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

**06.09.2006 Bulletin 2006/36**

(51) Int Cl.:

**A61K 31/353** <sup>(2006.01)</sup>**A61P 31/10** <sup>(2006.01)</sup>**A61P 31/04** <sup>(2006.01)</sup>**A61P 31/12** <sup>(2006.01)</sup>(21) Application number: **06012243.9**(22) Date of filing: **08.10.1999**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**

- **Medlen, Constance Elizabeth**  
**0084 Rietondale (ZA)**

(30) Priority: **08.10.1998 ZA 9809190****21.04.1999 ZA 9902848**(74) Representative: **Benson, John Everett****J. A. Kemp & Co.,****14 South Square,****Gray's Inn****London WC1R 5JJ (GB)**(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:**99970022.2 / 1 126 837**Remarks:

Diese Anmeldung ist am 14 - 06 - 2006 als

Teilanmeldung zu der unter INID-Kode 62 erwähnten

Anmeldung eingereicht worden.


(71) Applicant: **Pfeinsmith Limited****9490 Vaduz (LI)**

(72) Inventors:

- **Dekker, Johannes**

**0043 Faerie Glen (ZA)**(54) **Fulvic acid and its use in the treatment of viral infections**

(57) A pharmaceutical composition comprising fulvic acid, salt, ester or derivative thereof as active agent is disclosed. The composition is preferably administered orally or topically for treating a condition in a human or animal. The condition may, for example, be inflammation, acne, eczema or bacterial or fungal or viral infections.

**EP 1 698 333 A1**

**Description****BACKGROUND OF THE INVENTION**

5 [0001] This invention relates to fulvic acid and its use in the treatment of various conditions.

[0002] Humic substances are ubiquitous in nature and arise from the decay of plant and animal residues in the environment (MacCarthy *et al.* 1990). These substances can be divided into humic acid, fulvic acid and humin on the basis of the solubility in water as a function of pH. Fulvic acid is the fraction that is soluble in water under all pH conditions and is in general lower in molecular size and weight and lower in colour intensity than humic acids.

10 [0003] Humic substances commonly account for 50% of the dissolved organic carbon concentrations in stream water, of which 90 to 95 % are fulvic acids. Humic acids are 3 to 5 times more abundant in soils than fulvic acids (Stevenson, 1982), whereas fulvic acids are 9 to 10 times more abundant in water than humic acids (Malcolm, 1985).

[0004] Humic acids have been successfully used in the treatment of:

- 15 (i) hyperacidity and other gastric disturbances in humans (Reichert, 1966, Gramsch, 1961)  
 (ii) inflammation (Salz 1974, Motohisa *et al.*, 1974)  
 (iii) anemia and hypercholesterolemia (Soloveyva and Lotosh 1984)  
 (iv) Von Willebrand disease (Lopez-Fernandez *et al.*, 1992)

20 [0005] The possible application of fulvic acid in the treatment of human and animal diseases has, up to now, not been investigated.

[0006] Wang *et al.* (1996) studied the interaction between fulvic acids and active oxygen free radicals and found fulvic acids from peat were able to scavenge both superoxide and hydroxyl radical. It has also been shown that fulvic acids prevent the absorption of mutagens through the rat small intestine using a highly mutagenic furanone found in chlorinated water and an *in vitro* everted rat gut sac system (Clark and Chipman, 1995).

25 [0007] Although the presence of fulvic acids in the drinking water of certain parts of China has been coupled to the incidence of Kashin-Beck disease, this only occurred in conjunction with a selenium deficient diet (Peng and Xu, 1987).

[0008] United States Patents Nos. 4,999,202 and 5,204,368 disclose compositions having bacterial and bacteriostatic properties containing a fulvic acid, salt or derivative thereof as the active ingredient.

30 These compositions are described as being useful as disinfectants.

**SUMMARY OF THE INVENTION**

35 [0009] According to one aspect of the invention, there is provided a pharmaceutical composition comprising a fulvic acid, salt, ester or derivative thereof as the active ingredient.

[0010] The pharmaceutical composition may be provided for oral or topical administration to a subject.

[0011] In the case of topical administration, the composition may be provided in the form of a solution, paste, ointment, powder or any other form suitable for topical administration.

[0012] The subject may be a human or an animal.

40 [0013] Further according to the invention, there is provided the use of a fulvic acid, salt, ester or derivative thereof, in the treatment of a condition of a subject. The condition may, for example, be inflammation, acne, eczema or bacterial or fungal or viral infections.

[0014] The treatment of the condition may be by oral or topical administration.

[0015] The subject is typically a human or an animal.

45 [0016] The fulvic acid is preferably a fulvic acid derived from a wet coal oxidation process of the type described in US patent 4,912,256. Such a fulvic acid is hereinafter referred to as "oxifulvic acid or OFA".

[0017] Bergh *et al.* (1997) identified almost 50 different compounds, most of which were carboxylic acids, in oxifulvic acid. The compounds were mostly ordinary physiological metabolites with no evidence of any toxic compound in the product mixture.

50 [0018] A typical functional group analysis of oxifulvic acid is given below:

Total acidic groups:	11,5 - 15,5 meq/g
Carboxylic groups:	8,5 - 12,5 meq/g
Phenolic groups:	2,3 - 3,7 meq/g

55 [0019] In an example of the invention, a composition for topical application to a human or animal comprises 4,5 percent, or 9,0 percent, by mass of oxifulvic acid in an aqueous cream.

**BRIEF DESCRIPTION OF THE DRAWINGS****[0020]**

Figures 1 to 4 illustrate graphically the results of certain tests carried out on oxifulvic acid, and Figures 5A and 5B illustrate photographically the results of treating pyotraumatic dermatitis using an oxifulvic acid cream of the invention.

**DESCRIPTION OF EMBODIMENTS**

**[0021]** The active ingredient in the practice of the invention is a fulvic acid, salt, ester or derivative thereof. Oxifulvic acid, having the preferred functional group analysis mentioned above, has been subjected to a number of *in vitro* and *in vivo* studies and these are described hereinafter.

**THE EFFECTS OF OXIFULVIC ACID ON IMMUNE FUNCTIONS *IN VITRO*****The effects of oxifulvic acid on the production of oxidants by human neutrophils.**

**[0022]** Human neutrophils (separated on Ficoll) were treated with oxifulvic acid (at 12.5 and 25ug/ml) for 15 min at 37°C. The cells were stimulated with PMA (phorbol myristate acetate) (20ng/ml) and superoxide production determined by measuring the superoxide-inhibitable reduction of ferricytochrome C (1mM). A significant inhibition of superoxide production was observed at both concentrations tested (Table 1).

**TABLE 1 The effects of oxifulvic acid on PMA-activated neutrophil superoxide production**

Treatment	nmoles superoxide/10 <sup>6</sup> neutrophils/10 min*
<b>Resting</b>	
Control	0.072
<b>Stimulated (+PMA)</b>	
Control	67.2
+oxifulvic acid (12.5ug/ml)	59
(25ug/ml)	43
* average data of two experiments	

**[0023]** The superoxide scavenging activities of oxifulvic acid (at 25ug/ml) were determined using the hypoxanthine (1mM)/xanthine-oxidase (100mU/ml) enzymatic system to generate superoxide. Oxifulvic acid exhibited superoxide-scavenging activity (Table 2).

**TABLE 2 Superoxide scavenging activities of oxifulvic acid at 25 µg/ml.**

Treatment	nmoles superoxide*
Control	55.95
Oxifulvic acid	41.25
* average data of two experiments	

**The effects of oxifulvic acid on the proliferative response of a mixed lymphocyte culture**

**[0024]** These experiments were performed by co-culturing the lymphocytes of two different donors in both the presence and absence of serial dilutions of the experimental agent for 7 days. Oxifulvic acid caused a dose-related inhibition of cell growth (Figure 1).

**The effects of oxifulvic acid on interleukin 2 (IL-2) production by human lymphocytes.**

**[0025]** Phytohemagglutinin (PHA)-stimulated human lymphocyte cultures were treated with oxifulvic acid at 60, 80 and

100 µg/ml for 2 days, whereafter the cells were centrifuged and the supernatant assayed for IL-2 levels, using a Biotrak™ human interleukin 2 ELISA system from Amersham™ (Amersham International Plc, Buckinghamshire, England).  
**[0026]** Oxifulvic acid caused a statistically significant decrease in IL-2 production by stimulated lymphocytes at all three concentrations tested (Figure 2).

## EVALUATION OF OXIFULVIC ACID AS AN ANTI-INFLAMMATORY COMPOUND *IN VIVO*

### 1. Evaluation in dinitrofluorobenzene sensitized mice

**[0027]** The effects of oxifulvic acid (4.5 and 9% cream applied topically) in 2,4-dinitro-1-fluorobenzene (DNFB) sensitized mice were evaluated using 50 BALB C female mice (6-7 weeks old) according to the method described by Rheins *et al* (1987). The mice were sensitized by application of DNFB to the shaved abdomen, divided into 5 groups and challenged on the right ear 6 days later. The inflamed ears of the mice in each group were treated topically for two days with one of the following creams i.e. control cream, oxifulvic acid 4.5%, oxifulvic acid 9%, dichlophenac sodium 1% (Voltaren Emulgel®) and betamethasone 0.1% (Betnovate®). The thickness of the ear was measured with a clock gauge before the challenge and 24 and 48h later.

**[0028]** All four treatments caused a significant decrease in inflammation on both days (Figure 3). These results were confirmed microscopically after termination of the mice and embedding the affected ears in paraffin wax.

**[0029]** No signs of toxicity was observed during the two days of treatment with the two oxifulvie acid creams.

**[0030]** An experiment was also carried out to study the possible variation between creams derived from oxifulvic acid batches sampled from different runs (98100055 and 98110067) as well as from different batches (99030086 to 99030089) sampled on consecutive days from the same continuous run. In this study 7 groups of 5 mice per group were used. The first group was treated with control cream whereas the other 6 groups were treated with the above-described 6 different 9% oxifulvic acid creams. The results of this experiment are reflected in Figure 4.

**[0031]** Again no sign of toxicity was observed during the two days of treatment with the six oxifulvic acid creams.

**[0032]** Similar results were obtained as in the previous experiment. Oxifulvic acid, once again, caused a statistically significant inhibition of inflammation in this model. An analysis of variance (two-way ANOVA) was performed on the results obtained with the different oxifulvic acid creams. For day one the P value is 0.131 and day two 0.761. There was, therefore, no significant difference between the various samples tested.

### 2(a) Evaluation in pyotraumatic dermatitis in cats and dogs

**[0033]** This trial was done by Dr O J Botha, Hatfield Bird and Animal Hospital, Pretoria. Ten clinical cases were entered in the trial. To qualify for this trial the following entities had to be present on the skin of the animals: wheal, erythema, pruritis and pyogenesis. Lesions were classified as slight, mild or severe before treatment. No other treatment was allowed during the trial. Owners were supplied with the 9% oxifulvic acid cream and instructed to apply the cream twice a day to the affected areas. This treatment had to continue for seven days. The owners were asked to return exactly seven days after the treatment commenced and the cases were re-evaluated clinically, biopsied and photographed.

**[0034]** Decreased inflammation was observed clinically as well as pathologically in all 10 cases studied as can be seen from the histopathological investigation described hereinafter. No side effects were noted in any of the cases. In most cases it was noted that resolutions of the lesions were complete and did not recur. Only in one of the cases, described as a chronic and longstanding case, did the owner return after 3 days because the dog was still scratching extensively. A short-acting cortisone was then administered and the dog responded favourably. A typical example of the results obtained during this trial can be seen in Figure 5. These photographs were taken before and after the treatment of a dalmation dog with lesions on the left medial humerus. Before treatment (Figure 5A) severe wheal, erythema and pyogenesis were noted while after treatment (Figure 5B) an absence of erythema and pyogenesis and only very slight remaining wheal were noted. In addition, the biopsy lesions of the first biopsy were completely healed.

### 2(b) Histopathological investigation: skin biopsies: clinical study: topical ointment - 9% fulvic acid cream.

#### Method:

**[0035]** Clinical cases having lesions of allergic dermatitis and wet eczema were identified in different species of animal as shown in Table 3.

**TABLE 3 Information on clinical cases**

Lab no	Treatment group	Species
3973 A1	Control	Cat (house cat)
3973 A2	Treatment	Cat (house cat)
3973 B1	Control	Dog (Bull Mastiff)
3973 B2	Treatment	Dog (Bull Mastiff)
3973 C1	Control	Dog (Bull dog)
3973 C2	Treatment	Dog (Bull dog)
4991 A1	Control	Dog (Dalmation)
4991 A2	Treatment	Dog (Dalmation)
4991 B1	Control	Dog (Maltese)
4991 B2	Treatment	Dog (Maltese)
4991 C1	Control	Dog (St. Bernard)
4991 C2	Treatment	Dog (St. Bernard)
4991 D1	Control	Dog (Maltese)
4991 D2	Treatment	Dog (Maltese)

**[0036]** Biopsies of control lesions (prior to treatment) of approximately 3 mm were collected, fixed in formalin and followed up with biopsies as close as possible to the site of the previous biopsy following treatment.

**[0037]** The formalin-fixed skin-biopsies were processed according to standard routine methods used for histological studies, embedded in paraffin-wax and slices of 6µm each were prepared. All slices were coloured using the Haemotoxillin and Eosine staining method.

#### Histopathological findings:

**[0038]** The histopathological findings are shown in Table 4. The control samples were initially investigated for specific morphological lesions which were graded as indicated in Table 4. The biopsies of the treated lesions were evaluated similarly.

**[0039]** It must be kept in mind that in each case each lesion could only be compared to its original control lesion, due to the fact that the specific ethiology and morphological changes differed in each of the cases.

**TABLE 4 Histopathological findings: Clinical trials: Enerkom**

Case 3973 A1: Control lesion	Surface exudative dermatitis (3+) Ulceration (3 +) Dermal inflammation (2+)
Case 3973 A2: Treated lesion	Surface exudative dermatitis (-) Ulceration (-) Dermal inflammation (1 +)
Case 3973 B1: Control lesion	Hyperplastic epithelia (3 +) Hyperpigmentation (2+) Dermal inflammation (3 +)
Case 3973 B2: Treated lesion	Hyperplastic epithelia (-) Hyperpigmentation (1+) Dermal inflammation (1+)
Case 3973 C1: Control lesion	Surface exudation (3 +) Hyperplastic epidermis(3 +) Dermal inflammation (3 +)

# EP 1 698 333 A1

(continued)

Case 3973 C2: Treated lesion	Surface exudation (-) Hyperplastic epidermis (3+) Dermal inflammation (1 +)
Case 4991A1: Control lesion	Ulceration and exudation (2+) Hyperplastic epidermis (2+) Dermal inflammation (2+)
Case 4991A2: Treated lesion	Ulceration and exudation (-) Hyperplastic epidermis (1+) Dermal inflammation (1 +)
Case 4991 B1: Control lesion	Surface exudation (2 +) Hyperplastic epidermis (2+) Dermal inflammation (2+)
Case 4991 B2: Treated lesion	Surface exudation (-) Hyperplastic epidermis (2+) Dermal inflammation (2+)
Case 4991 C1: Control lesion	Surface exudative dermatitis (3+) Ulcerative boils (2+) Hyperplastic epidermis (2+) Dermal inflammation (3+)
Case 4991 C2: Treated lesion	Surface exudative dermatitis (-) Ulcerative boils (-) Hyperplastic epidermis (3+) Dermal inflammation (1 +)
Case 4991 D1: Control lesion	Hyperplastic epidermis (3 +) Dermal inflammation (3+)
Case 4991 D2: Treated lesion	Hyperplastic epidermis (3+) Dermal inflammation (1 +)
Key: - absent 1+ light 2+ medium 3+ severe	

## Conclusion:

**[0040]** These results must be interpreted as being histopathological observations only. These results are presented in addition to the clinical observations of the lesions that were treated.

**[0041]** In general, and with due regard to the abovementioned limitations, it appears as if healing was promoted and inflammation reduced in the treated lesions.

**[0042]** The surface (shallow) exudative dermatitis (acute inflammation) did show accelerated healing in all cases. Hyperplastic epidermis (acantosis) is a chronic condition and thus showed little change upon treatment. The degree of dermal inflammation was also reduced in all except one of the treated lesions when compared to the original untreated lesions.

**[0043]** There were no controls or lesions that were left untreated for the same period of time as the treated lesions. Spontaneous healing can thus not be excluded as a contributing factor when interpreting these results.

## TOXICITY STUDIES IN EXPERIMENTAL ANIMALS

[0044] The applicant has undertaken acute and chronic toxicity studies which served to prove the safety and very low toxicity of oxifulvic acid.

[0045] Acute oral and dermal toxicity studies, acute dermal and eye irritation studies, skin sensitization studies as well as subchronic oral and dermal toxicity studies, in which the oxifulvic acid solution (25.4% concentrate) and the oxifulvic acid cream (formulated to contain 5,33% oxifulvic acid in this particular instance) were evaluated. The results of the investigations are summarized in Tables 5 and 6.

**TABLE 5 25,4% Oxifulvic acid toxicity studies**

STUDY NUMBER	TYPE OF STUDY	RESULTS
1388	Acute oral toxicity in rats	LD <sub>50</sub> value > 3380 mg/kg
1389	Acute dermal toxicity in rats	LD <sub>50</sub> value > 5712 mg/kg
1390	Acute dermal irritation	Non-irritant
1391	Acute eye irritation	Non-irritant
1392	Skin sensitization	Weak skin sensitizer
1520	Subchronic oral toxicity in rats (90 day study)	Highest dose tested was 1000 mg/kg/day. No deaths or sick animals. Slight alterations in blood chemistry and slight decreases in body masses.
1530	Subchronic dermal toxicity in rats (90 day study)	Highest dose tested was 1000 mg/kg/day (of the active substance). No deaths or sick animals. Slight alterations in blood chemistry and slight decreases in body masses.

**TABLE 6 5,33% Oxifulvic acid cream toxicity studies**

STUDY NUMBER	TYPE OF STUDY	RESULTS
1393	Acute oral toxicity in rats	LD <sub>50</sub> value > 4147 mg/kg
1394	Acute dermal toxicity in rats	LD <sub>50</sub> value > 8599 mg/kg
1395	Acute dermal irritation in rabbits	Slight irritant
1396	Acute eye irritation in rabbits	Non-irritant
1397	Skin sensitization in guinea pigs	Moderate skin sensitizer
1512	Subchronic dermal toxicity in rats (90 day study)	Highest dose tested was 1000 mg/kg/day. No deaths or sick animals. Slight alterations in blood chemistry and local irritation at site of application

### Discussion

[0046] The data shows that none of the products produced any measurable toxicity during the acute dermal or oral exposure tests.

[0047] During the sub-chronic oral and dermal toxicity studies with both substances very high doses were used. Animals were dosed with 1000 mg/kg/day of the active substance in the oxifulvic acid study. The 5,33% oxifulvic acid cream was applied to the skin of rats at a dose rate of 1000 mg/kg/day for a period of 90 days. No abnormal clinical signs were noticed and none of the animals died during the studies. The changes in the clinical pathology and body masses in the animals receiving the test item were relatively small.

## THE ANTIMICROBIAL PROPERTIES OF OXIFULVIC ACID

[0048] The antimicrobial properties of an oxifulvic acid solution (25.4 percent by mass of the fulvic acid) and a 4,5 percent by mass oxifulvic acid cream were evaluated *in vitro* on a number of well known pathogens. The results obtained are presented in Tables 7 and 8. The symbol + denotes growth, and the symbol - denotes no growth.

TABLE 7 Antimicrobial activity of 25.4% oxifulvic acid solution

Organism	Dilution			
	1:2	1:10	1:20	1:40
$\beta$ -Hemolytic <i>streptococcus</i>	-	-	-	+
<i>Streptococcus faecalis</i>	-	-	-	+
<i>Klebsiella pneumoniae</i>	-	-	-	+
<i>Pseudomonas aeruginosa</i>	-	-	-	-
<i>Candida spp.</i>	-	-	-	+
<i>Escherichia coli</i>	-	-	+	+
<i>Proteus mirabilis</i>	-	-	-	+
<i>Staphylococcus aureus</i>	-	-	+	+

TABLE 8 Antimicrobial activity of 4,5% oxifulvic acid cream

Organism	Dilution		
	1:2	1:10	1:20
$\beta$ -Hemolytic <i>streptococcus</i>	-	+	+
<i>Streptococcus faecalis</i>	-	+	+
<i>Klebsiella pneumoniae</i>	-	+	+
<i>Pseudomonas aeruginosa</i>	-	+	+
<i>Candida spp.</i>	-	+	+
<i>Escherichia coli</i>	-	+	+
<i>Proteus mirabilis</i>	-	+	+
<i>Staphylococcus aureus</i>	-	+	+

[0049] Further, the efficacy of the 4,5 percent oxifulvic acid cream and a 25,4 percent by mass oxifulvic acid solution to inhibit the growth of bacteria and fungi was tested in accordance with the SABS method 730 (*in vitro*) on a few test organisms. The results obtained are set out in Table 9.

TABLE 9 Bacteriostatic and fungistatic efficacy of 4,5% oxifulvic acid cream and 25,4% oxifulvic acid solution

Samples	Dilution	Diameters (mm) of the zones of inhibition					
		<i>Pseudomonas aeruginosa</i>	<i>Escherichia coli</i>	<i>Staphylococcus aureus</i>	<i>Aspergillus niger</i>	<i>Candida albicans</i>	<i>Streptococcus pyogenes</i>
Solution	25,4%	29,4	29,36	>29,0	18,83	18,36	22,71
Solution	5000ppm	N/T	N/T	N/T	No zone	No zone	N/T
Solution	1000ppm	No zone	No zone	No zone	N/T	N/T	N/T
Solution	500ppm	No zone	No zone	No zone	N/T	N/T	N/T
Cream	4,5%	15,6	14,74	28,8	9,66	9,58	13,39
N/T = not tested							

[0050] From the foregoing studies it can be seen that oxifulvic acid exhibits some measure of antimicrobial activity or bacteriostatic or fungistatic efficacy against some of the test organisms, even when formulated in a cream.

[0051] The 4.5 percent oxifulvic acid cream was subjected to a preservative efficacy test by the Microbiological Division of the SABS and it was found that the cream complied with the requirements of the USP 23 (1995).

## ANTIVIRAL ACTIVITY OF OXIFULVIC ACID

### Methods:

[0052] The following viruses were tested:

- Human herpes simplex virus type 1
- Human adenovirus type 2
- Simian rotavirus SA11
- Poliovirus type 1 Sabin vaccine strain
- Coxsackie B virus type 1 laboratory strain
- Coxsackie A virus type 9 laboratory isolate

[0053] Viruses were grown in either vervet monkey kidney cells or a primary liver cancer cell line (PLC/PRF/5). Stock virus suspensions were titrated to establish their titre and to prepare a viral suspension containing 100 X 50% tissue culture infectious dose (100TCID<sub>50</sub>)/200µl.

[0054] *Prevention of binding of viruses to the host cell:* Monolayers of the appropriate cell cultures in 96-well microtitre trays were washed and starved for a minimum of 1 hr in serum-free MEM. After starvation, doubling dilutions of oxifulvic acid in serum-free MEM were added to each well together with 100TCID<sub>50</sub> virus. The microtitre trays were incubated at 37°C and examined daily, for 7 days, for CPE. Wells inoculated with 100TCID<sub>50</sub> viruses and no oxifulvic acid acted as positive controls.

The appearance of CPE indicated that no inhibition of binding had taken place.

[0055] *Inhibition of viral replication in the host cell:* Monolayers of the appropriate cell cultures in 96-well microtitre trays were washed and starved for a minimum of 1 hr in serum-free MEM. After starvation 100TCID<sub>50</sub> virus was added to all wells and allowed to adsorb for 1-2hrs. After adsorption, the unadsorbed viruses were washed from the wells using serum-free MEM. Thereafter doubling dilutions of oxifulvic acid, in serum-free MEM, were added to the appropriate wells. The microtitre trays were incubated at 37°C and examined daily, for 7 days, for CPE. Wells inoculated with 100TCID<sub>50</sub> viruses and no oxifulvic acid acted as positive controls. The appearance of CPE indicated that no inhibition of viral replication had taken place.

### Results:

[0056] The effects of oxifulvic acid on the binding of viruses to the host cells as well as on the replication of viruses can be seen in Tables 10A and 10B.

**TABLE 10A Effects of oxifulvic acid on the binding of viruses to the host cells**

Virus	Lowest concentration at which 100% viral inhibition was noted at day 6 or 7 post infection (mg/ml)	Lowest concentration at which limited viral inhibition was noticed (mg/ml)
Herpes simplex virus type 1	1.875	0.234
Human adenovirus type 2	3.75	0.937
Simian rotavirus SA 11	1.875	0.058
Polio virus type 1	1.875	0.468
Coxsackie B virus type 1	1.875	0.937
Coxsackie A virus type 9	1.875	1.875

**TABLE 10B Effects of oxifulvic acid on the replication of viruses**

Virus	Lowest concentration at which 100% viral inhibition was noted at day 6 or 7 post infection	Lowest concentration at which limited viral inhibition was noticed
Herpes simplex virus type 1	1.875	0.937
Human adenovirus type 2	3.75	1.875
Simian rotavirus SA 11	3.75	0.234
Polio virus type 1	0.468	0.234
Coxsackie B virus type 1	1.875	0.937
Coxsackie A virus type 9	1.875	0.468

## Discussion

[0057] Oxifulvic acid prevented the binding of the six experimental virus cultures between 1.87mg/ml and 3.75mg/ml whereas inhibition of viral replication was inhibited at concentrations between 0.469mg/ml and 3.75mg/ml. Limited inhibition of viral replication was noted at a concentration as low as 0.103mg/ml in the case of simian rotavirus SA 11.

**Oxifulvic acid is therefore a compound that**

[0058]

- i) scavenges the neutrophil-derived pro-inflammatory reactive oxidant superoxide;
- ii) decreases production of the lymphocyte-derived pro-inflammatory cytokine IL-2;
- iii) inhibits a mixed lymphocyte reaction typical of a transplanted organ rejection reaction;
- iv) has *in vitro* activity against Gram positive, Gram negative, as well as fungal and viral human pathogens;
- v) inhibits a contact hypersensitivity reaction induced in dinitrofluorobenzene sensitized mice as effectively as generally used anti-inflammatory agents such as dichlophenac sodium and betamethasone (these two agents are however associated with serious adverse side effects);
- vi) has *in vivo* anti-inflammatory activity against pyotraumatic dermatitis in cats and dogs; and
- vii) has very low toxicity in experimental animals.

## REFERENCES

[0059]

1. Bergh J J, Cronjé I J, Dekker J, Dekker T G, Gerritsma ML and Mienie L. 1997. Non catalytic oxidation of water-slurried coal with oxy;gen: identification of fulvic acids and acute toxicity. *Fuel*, 76 (2):149-154.
2. Clark N N, Chipman J K. 1995. Absorption of 3-chloro-4-(dichloromethyl)-5-hydroxy-2[5H] furanone (MX) through rat small intestine in vitro. *Toxicol Lett*, 81(1):33-38.
3. Gramsch H. 1961. Ein Beitrag zur Behandlung der Gastropatien. *Med Monatsschr*, 15:658-687
4. Lopez-Fernandez M F, Blanco-Lopez M J, Castineira M P, Batlle J. 1992. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII. *Am J Hematol*, 40:20-27.
5. MacCarthe P, Clapp C E, Malcolm R L, Bloom P R. 1990. Humic substances in soil and crop sciences: selected readings. Proceedings of a symposium by International Humic substances Society, Soil Science Society of America, American society of Agronomy and Crop Science Society of America, Chicago, Illinois, 2 December 1985.
6. Malcolm R L. 1985. The geochemistry of stream fulvic and humic substances p. 181-209. In Aiken G R et al (ed.) *Humic substances in soil, sediment and water: Geochemistry isolation and characterization*. Wiley-Interscience, New York.

7. Motohisa S, Yoshinori H, Shuzo K. 1974. Humic acids for treatment of skin disorders, In: C A 80, p.283 100222u, Patent Japan. Kokai 7392, 524.

8. Peng A, Xu L Q. 1987. The effects of humic acid on the chemical and biological properties of selenium in the environment. Sci Total Enviro, 64(1-2):89-98.

9. Reichert B. 1966. Huminsäuren und ihre Derivate in der modernen Therapie. Dtsh Apoth, 18:204-206.

10. Rheins L A, Barnes B, Amornsiripanitch S, Collins C E, Nordlund J J. 1987. Suppression of the cutaneous immune response following topical application of prostaglandin PGE2.

11. Salz H. 1974. Salhumin-Gel, ein Lokalthérapeutikum mit hyperämischer, entzündungshemmender und analgetischer Wirkung. Med Monatsschr, 28:548-530.

12. Solovyeva V P, Lotosh T D. 1984. Biologically active peat substances body resistance stimulators. Dublin: Ireland. Proceedings of the 7th International Peat congress, 4, 428-434.

13. Stevenson F J. 1982. Humus chemistry: Genesis, composition, reactions. Chapter 9. Reactive functional groups of humic substances. Wiley-Interscience, New York.

14. Wang C, Wang Z, Peng A, Hou J, Xin W. 1996. Interaction between fulvic acids of different origins and active oxygen radicals. Sci China C Life Sci, 39(3):267-275.

## Claims

1. The use of fulvic acid, salt, ester or derivative thereof in the manufacture of a medicament for treatment in humans and animals of viral infections.
2. The use according to claim 1 wherein the medicament is for oral or topical administration.
3. The use according to claim 2 wherein the medicament is provided in the form of a solution, paste, ointment, powder or any other form suitable for topical administration.
4. The use according to any one of claims 1 to 3 wherein the fulvic acid, salt, ester or derivative thereof is an oxifulvic acid, salt, ester or derivative thereof.
5. The use according to claim 4 wherein the oxifulvic acid, salt, ester or derivative thereof has the following functional group analysis:

Total acidic groups:	11.5 - 15.5 meq/g
Carboxylic groups:	8.5 - 12.5 meq/g
Phenolic groups:	2.3 - 3.7 meq/g

Fig 1





Fig 2








Fig 3

4




5A

Case 4 – Before treatment



5B

Case 4 – Seventh day after treatment





European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 06 01 2243

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	DE 28 50 685 A (KNEER FRANZ X) 4 June 1980 (1980-06-04) * claim 1 *	1-5	INV. A61K31/353 A61P31/10 A61P31/04 A61P31/12
A	----- DATABASE WPI Section Ch, Week 199417 Derwent Publications Ltd., London, GB; Class B04, AN 1994-140953 XP002127438 & JP 06 087752 A (KYOWA KAGAKU KOGYO KK) 29 March 1994 (1994-03-29) * abstract *	1-5	
A	----- DATABASE WPI Section Ch, Week 199721 Derwent Publications Ltd., London, GB; Class B05, AN 1997-226868 XP002127439 & CN 1 097 990 A (KANG H) 1 February 1995 (1995-02-01) * abstract *	1-5	
P,A	----- DATABASE WPI Section Ch, Week 199913 Derwent Publications Ltd., London, GB; Class D13, AN 1999-146250 XP002127440 & JP 11 009674 A (KOGA K) 19 January 1999 (1999-01-19) * abstract *		TECHNICAL FIELDS SEARCHED (IPC)  A61K A61P
P,A	----- DATABASE EPDOC EUROPEAN PATENT OFFICE; CN1216335 14 April 1999 (1999-04-14), ZHU YAUIN: "Prepn. of medicinal-grade peat sodium fulvic acid" XP002127437 * abstract *	1-5	
		-/--	
The present search report has been drawn up for all claims			
Place of search <b>Munich</b>		Date of completion of the search <b>31 July 2006</b>	Examiner <b>Herrera, S</b>
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document	

2  
EPO FORM 1503 03.82 (P04C01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 06 01 2243

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	& CN 1 213 665 A (ZHU YAQUIN) 14 April 1999 (1999-04-14) ----- WO 97/49288 A (BAVERSTOCK MICHAEL GEORGE DOUG ;ORGANOCURE PROPRIETARY LIMITED (ZA) 31 December 1997 (1997-12-31) * page 2, lines 1-7 *	1-5	
A	----- GB 2 244 215 A (NAT ENERGY COUNCIL) 27 November 1991 (1991-11-27) * page 4, line 22 - page 5, line 10 * * pages 8-9 * -----		
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search <b>Munich</b>		Date of completion of the search <b>31 July 2006</b>	Examiner <b>Herrera, S</b>
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... &amp; : member of the same patent family, corresponding document</p>			

2  
EPO FORM 1503 03 B2 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 06 01 2243

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

31-07-2006

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 2850685	A	04-06-1980	NONE	
JP 6087752	A	29-03-1994	NONE	
CN 1097990	A	01-02-1995	NONE	
JP 11009674	A	19-01-1999	NONE	
CN 1213665	A	14-04-1999	NONE	
WO 9749288	A	31-12-1997	AU 726234 B2	02-11-2000
			AU 2754997 A	22-01-1998
			AU 3269197 A	14-01-1998
			AU 3411497 A	14-01-1998
			BR 9709989 A	11-01-2000
			BR 9709994 A	25-01-2000
			CA 2258495 A1	31-12-1997
			CA 2258534 A1	31-12-1997
			EP 0918462 A1	02-06-1999
			EP 0907624 A1	14-04-1999
			JP 2000512987 T	03-10-2000
			JP 2001501899 T	13-02-2001
			NO 985999 A	18-02-1999
			NO 986041 A	26-02-1999
			NZ 333440 A	28-04-2000
			NZ 333443 A	28-04-2000
			PL 330925 A1	07-06-1999
			PL 330926 A1	07-06-1999
			TR 9802702 T2	21-05-1999
			TR 9802706 T2	21-05-1999
			WO 9749651 A1	31-12-1997
GB 2244215	A	27-11-1991	AU 638575 B2	01-07-1993
			AU 7726491 A	28-11-1991
			DE 4116853 A1	05-12-1991
			FR 2662333 A1	29-11-1991
			IT 1247945 B	05-01-1995
			JP 3015508 B2	06-03-2000
			JP 4235107 A	24-08-1992
			US 5204368 A	20-04-1993

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82